Adalimumab vs Etanercept in Quality of Life Improvement

• Adalimumab showed a slightly higher reduction in PASI after 1 year, however it proved an equivalent efficacy to Etanercept after an extensive follow-up (up to 5 years)
• Contrarily to etanercept, adalimumab patients showed a progressive improvement with DLQI (84 to 77)
• For both groups, sustained response (PASI75 maintenance of results 60 months after initiation of treatment. (1 exception).

• Comment of increased improvement in DLQI for adalimumab: this might be explained by the lower treatment frequency of injections with adalimumab when compared to etanercept. Also further studies will be needed to validate this small study (41 subjects)

Contributors

Dr Christophe Hsu – dermatologist. Geneva, Switzerland

Source of information: p330 Comparative PASI and DLQI evolution of psoriasic patients treated with HUMIRA vs ENBREL Dutei A.M. et al. EADV Annual Meeting (2014), Amsterdam The Netherlands